TOP HEADLINES

Editor's Corner

GSK's ViiV turns to Chinese company for cheap supply of Tivicay API

The HIV-oriented joint venture of Pfizer, GlaxoSmithKline and Japan's Shionogi is turning to a Chinese manufacturer for a cheap supply of dolutegravir, the active ingredient in its Tivicay. The deal is seen as a way to cut the cost in China and some other developing countries of the JV's newest HIV fighter.

FDA warning letter lays out cross-contamination issues at Canada plant

In April, Health Canada closed an active pharmaceutical ingredient repackager in Toronto and had it recall hundreds of bulk APIs that the regulators said could have been cross-contaminated by penicillin. Now the FDA has weighed in with a warning letter for the company.

Listen up, eardrop makers: FDA says get products approved or face prosecution

On Wednesday, the FDA announced a federal permanent injunction against a company that continued to sell suppositories after being repeatedly warned they needed to be evaluated and approved by the FDA. Separately, it warned makers of unapproved children's eardrops they may face prosecution if they don't stop selling them.

Lonza expands New Hampshire plant to make Alexion products

While U.S. drugmaker Alexion is building up its manufacturing operations in Europe, French CMO Lonza will do the same for Alexion in the U.S.

Sanofi to improve environmental impact of its manufacturing plants

Drugmakers have paid ever-increasing attention to the environmental impact their manufacturing operations have, looking for ways to lower their carbon footprint and to be improve energy efficiency. Toward that end, France's Sanofi said today that it has a three-year deal to have SUEZ environment improve the environmental and cost performance of its manufacturing sites globally.

MORE NEWS

From Our Sister Sites

FierceAnimalHealth

The U.S. Department of Agriculture has amended its rules to allow veterinarians to make vaccines in their offices for individual clients, so long as compounds aren't contracted out to unlicensed manufacturers.

FierceBiotech

A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.